BR112015014034A2 - inibidores de irak e usos dos mesmos - Google Patents

inibidores de irak e usos dos mesmos

Info

Publication number
BR112015014034A2
BR112015014034A2 BR112015014034A BR112015014034A BR112015014034A2 BR 112015014034 A2 BR112015014034 A2 BR 112015014034A2 BR 112015014034 A BR112015014034 A BR 112015014034A BR 112015014034 A BR112015014034 A BR 112015014034A BR 112015014034 A2 BR112015014034 A2 BR 112015014034A2
Authority
BR
Brazil
Prior art keywords
enzymes
irak inhibitors
irak
inhibitors
family
Prior art date
Application number
BR112015014034A
Other languages
English (en)
Inventor
E Masse Craig
Lee Romero Donna
C Harriman Geraldine
robert greenwood Jeremy
Shelley Mee
T Wester Ronald
Kapeller-Libermann Rosana
Robinson Shaughnessy
Original Assignee
Nimbus Iris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Iris Inc filed Critical Nimbus Iris Inc
Publication of BR112015014034A2 publication Critical patent/BR112015014034A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

resumo patente de invenção: "inibidores de irak e usos dos mesmos". a presente invenção refere-se a compostos, composições dos mesmos, e métodos de uso dos mesmos. a busca por novos agentes terapêuticos tem sido bastante auxiliada nos últimos anos por uma melhor compreensão da estrutura das enzimas e outras biomoléculas associadas a doenças. uma classe importante de enzimas que constitui a matéria de extenso estudo é a da família das quinases proteicas.
BR112015014034A 2013-01-10 2014-01-08 inibidores de irak e usos dos mesmos BR112015014034A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751000P 2013-01-10 2013-01-10
PCT/US2014/010652 WO2014110114A1 (en) 2013-01-10 2014-01-08 Irak inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112015014034A2 true BR112015014034A2 (pt) 2017-07-11

Family

ID=51061425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014034A BR112015014034A2 (pt) 2013-01-10 2014-01-08 inibidores de irak e usos dos mesmos

Country Status (9)

Country Link
US (2) US9175007B2 (pt)
EP (1) EP2943202A4 (pt)
JP (1) JP2016505012A (pt)
CN (1) CN105142639A (pt)
AU (1) AU2014205577A1 (pt)
BR (1) BR112015014034A2 (pt)
CA (1) CA2890911A1 (pt)
HK (1) HK1216859A1 (pt)
WO (1) WO2014110114A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153311A (zh) 2010-06-03 2013-06-12 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
BR112015014034A2 (pt) * 2013-01-10 2017-07-11 Nimbus Iris Inc inibidores de irak e usos dos mesmos
BR112016006319A2 (pt) 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
EP3052485B1 (en) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019001461A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 Irak4抑制剂
EP3645525A1 (en) 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2021016293A1 (en) * 2019-07-22 2021-01-28 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
WO2023075479A1 (ko) * 2021-10-28 2023-05-04 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1937459A1 (de) 1968-08-02 1970-02-05 Ciba Geigy Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
CN1346358A (zh) * 1999-03-30 2002-04-24 日本曹达株式会社 噻吩并嘧啶化合物及其盐和制备方法
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
MXPA03009925A (es) 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
WO2003057149A2 (en) 2001-12-28 2003-07-17 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
EP1622914B1 (en) 2003-03-31 2011-06-01 Trovis Pharmaceuticals LLC New piperidinylamino-thieno[2,3-d] pyrimidine compounds
WO2005037213A2 (en) 2003-10-14 2005-04-28 Cornell Research Foundation, Inc. Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
ES2341559T3 (es) 2004-07-23 2010-06-22 The Medicines Company (Leipzig) Gmbh Pirido(3',2':4,5)tieno(3,2-d)pirimidinas y pirido(3',2':4,5)furo(3,2-d)pirimidinas sustituidas para su utilizacion como inhibidores de la liberacion de pda-4 y/o tnf-alfa.
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
EP1899353A1 (en) 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
JP2009504752A (ja) 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式ｍＧｌｕＲ１アンタゴニスト
EP1931683B1 (en) 2005-08-19 2011-07-13 Schering Corporation Fused tricyclic mglur1 antagonists as therapeutic agents
CA2668997C (en) * 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
TW201024307A (en) 2008-09-10 2010-07-01 Kalypsys Inc Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2509597A4 (en) 2009-12-10 2013-04-10 Univ North Carolina SELECTIVE ETA-GLUCURONIDASE INHIBITORS AS TREATMENT AGAINST THE SIDE EFFECTS OF CAMPTOTHECIN-DERIVED ANINEOPLASTIC AGENTS
EP3252054A1 (en) 2010-07-13 2017-12-06 F. Hoffmann-La Roche AG Pyrazolo[1,5a]pyrimidine derivatives as irak4 modulators
CA2808432C (en) 2010-07-23 2019-06-04 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds with thieno[2,3-d]pyrimidine core
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
ES2575143T3 (es) 2011-11-23 2016-06-24 Cancer Research Technology Limited Inhibidores de tienopiridina de la proteína quinasa C atípica
TWI589579B (zh) 2012-01-10 2017-07-01 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
WO2014011902A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2872518A4 (en) 2012-07-11 2016-05-18 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
BR112015014034A2 (pt) * 2013-01-10 2017-07-11 Nimbus Iris Inc inibidores de irak e usos dos mesmos
WO2014194242A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof
WO2014194201A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2890911A1 (en) 2014-07-17
US9175007B2 (en) 2015-11-03
WO2014110114A1 (en) 2014-07-17
US20160068543A1 (en) 2016-03-10
JP2016505012A (ja) 2016-02-18
US9751892B2 (en) 2017-09-05
HK1216859A1 (zh) 2016-12-09
EP2943202A4 (en) 2016-08-24
US20140194417A1 (en) 2014-07-10
CN105142639A (zh) 2015-12-09
EP2943202A1 (en) 2015-11-18
AU2014205577A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
BR112015014034A2 (pt) inibidores de irak e usos dos mesmos
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
TR201901886T4 (tr) DNA-PK inhibitörleri.
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
EA201592198A1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690760A1 (ru) Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
NI201500140A (es) Compuestos y composiciones terapéuticos
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2496 DE 06/11/2018.